Mounting preclinical evidence indicates that CDK4/6i sensitise in vitro and in vivo models to anti‐PD‐1 blockade, mainly via stimulation of tumour cell antigen presentation, inhibition of the proliferative capacity of T regulatory cells and increase of T cell inflammatory signatures.226, 227, 228. Here, CDK4 is linked to neoplasm.